Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial

医学 利拉鲁肽 双盲 内科学 胃肠病学 临床试验 胆汁酸 糖尿病 内分泌学 替代医学 安慰剂 2型糖尿病 病理
作者
Martin L. Kårhus,Andreas Brønden,Julie Lyng Forman,Anne Haaber,Elisabeth Knudsen,Ebbe Langholz,Lars Ove Dragsted,Svend Høime Hansen,Martin Krakauer,Tina Vilsbøll,David P. Sonne,Filip K. Knop
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:7 (10): 922-931 被引量:44
标识
DOI:10.1016/s2468-1253(22)00198-4
摘要

Summary

Background

Bile acid diarrhoea is an underdiagnosed disease estimated to affect 1–2% of the general population. Case reports indicate that the glucagon-like peptide 1 receptor agonist liraglutide might be an effective treatment for bile acid diarrhoea. We aimed to investigate the safety and efficacy of liraglutide for the treatment of bile acid diarrhoea.

Methods

We conducted a randomised, double-blind, active-comparator, double-dummy, non-inferiority clinical trial at the Center for Clinical Metabolic Research at Copenhagen University Hospital–Herlev and Gentofte, Hellerup, Denmark. Patients aged 18–75 years with 75selenium-homotaurocholic acid test (SeHCAT)-verified moderate-to-severe primary bile acid diarrhoea were randomly assigned (1:1) to receive liraglutide (one daily subcutaneous injection uptitrated from 0·6–1·8 mg per day over 3 weeks) or colesevelam (three capsules of 625 mg twice daily), the standard of care, for 6 weeks following one run-in week with no treatment. The primary endpoint was the proportion of participants experiencing a reduction in daily stool frequency of 25% or greater after 6 weeks. Data from all participants were included in the analysis of the primary outcome. The non-inferiority limit was set to 15% in favour of colesevelam. This trial is registered with EudraCT (2018-003575-34) and is completed.

Findings

Between April 1, 2019, and Jan 31, 2021, 52 patients were enrolled; 26 were assigned to liraglutide and 26 to colesevelam. 20 (77%) of 26 participants on liraglutide and 13 (50%) of 26 on colesevelam experienced a 25% or greater reduction in stool frequency, corresponding to a significant risk difference of −27% in favour of liraglutide (one-sided 95% CI −100 to −6). Liraglutide was therefore superior to colesevelam in reducing daily stool frequency. Mild nausea with a duration of 10–21 days was reported by six participants in the liraglutide group and by one participant in the colesevelam group. No other adverse events were reported.

Interpretation

The superiority of liraglutide compared with colesevelam in reducing stool frequency suggests consideration of liraglutide as a potential new treatment modality for bile acid diarrhoea, although larger confirmatory trials powered for superiority are warranted.

Funding

Novo Nordisk, Novo Nordisk Foundation, Foundation for the Advancement of Medical Science under The A.P. Møller and Chastine Mc-Kinney Møller Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lydia完成签到,获得积分10
刚刚
1秒前
lzh发布了新的文献求助10
2秒前
2秒前
我是老大的应助被淡淡采纳,获得10
3秒前
3秒前
mof发布了新的文献求助10
3秒前
桐桐的应助被谨慎笑阳采纳,获得10
4秒前
4秒前
xiaoting完成签到,获得积分20
4秒前
涨誊完成签到,获得积分10
5秒前
5秒前
庄冬丽完成签到,获得积分10
6秒前
6秒前
zsn发布了新的文献求助10
7秒前
7秒前
奋斗忆南完成签到,获得积分10
7秒前
wt完成签到,获得积分10
7秒前
我是老大的应助被tqdwxawa采纳,获得10
7秒前
7秒前
7秒前
8秒前
8秒前
zhiren发布了新的文献求助10
9秒前
爆米花的应助被mof采纳,获得10
9秒前
master发布了新的文献求助10
9秒前
10秒前
大模型的应助被西陆采纳,获得10
10秒前
酤贳完成签到 ,获得积分10
10秒前
XY关注了科研通微信公众号
10秒前
11秒前
12秒前
共享精神的应助被科研通管家采纳,获得10
13秒前
英姑的应助被科研通管家采纳,获得10
13秒前
SciGPT的应助被grace采纳,获得10
13秒前
Jun的应助被科研通管家采纳,获得10
13秒前
我是老大的应助被科研通管家采纳,获得10
14秒前
共享精神的应助被科研通管家采纳,获得10
14秒前
爆米花的应助被科研通管家采纳,获得10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183508
求助须知:如何正确求助?哪些是违规求助? 9572862
关于积分的说明 21827639
捐赠科研通 7780681
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480405